Dr. Longo is Chairman of the Board and founder of PharmatrophiX. Dr. Longo received his MD in 1981 and PhD in Neurosciences in 1983 from UC San Diego. He completed his neurology training in the Department of Neurology at UC San Francisco where he was then recruited as an assistant professor and promoted to professor and vice chair. From 2001 to 2005 he was chair of the Department of Neurology at the University of North Carolina-Chapel Hill and served as chair of the Department of Neurology and Neurological Sciences at Stanford University from 2006-2023. With support from the Alzheimer's Drug Discovery Foundation, Alzheimer's Association, Eastern North Carolina Chapter of the Alzheimer’s Association, the NIH-National Institute on Aging and generous donations, he and his team, along with co-inventor Dr. Stephen Massa MD, PhD at UCSF & the SFVAMC, pioneered the development of small molecules targeting neurotrophin receptors for the treatment of Alzheimer's, Huntington’s diseases and other disorders. In 2005, while at UNC, he founded PharmatrophiX for the focus on commercial development of such compounds. Dr. Longo is the inaugural recipient of the Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. Dr. Longo serves in many advisory capacities including the National Advisory Council on Aging, NIH study sections, Pfizer Ventures, editorial boards, foundations, grant review boards and therapy evaluations.

Frank M. Longo, M.D., Ph.D.

Anne Chun Longo

Anne Longo has been CEO of PharmatrophiX since 2006 and also serves as the Senior Director of Development for Stanford Medicine. Following her graduation from Stanford University, she led programs at the NIH and at the Alliance for Aging Research in Washington DC. Ms. Longo also served in business development at Age Wave and at Charles Schwab in San Francisco. As CEO of PharmatrophiX, Ms. Longo develops and executes funding models, oversees finances working with the CFO, manages commercial projects and supervises contract research organization (CRO) projects. She has worked in medical development since March 2002 where she served as the Director of Development for the Department of Neurology at the University of North Carolina-Chapel Hill and then worked as the Director of Development at Stanford University for Women's Cancer and the Neurosciences beginning in May 2006. In her twenty-three years of medical development, Ms. Longo has raised over $320M in new gifts including 14 endowed medical school professorships.

The PharmatrophiX Team

Kathy Huff joined Pharmatrophix in August 2022. As a financial executive with over 25 years of experience, Ms. Huff spent several years in public accounting as a CPA before moving on to the private sector. She began her career at Ernst & Young in Columbus, Ohio and worked for several local public accounting firms over the next few years in CA, AL and NC before moving over to the private sector. During the past 15 years, she has worked primarily with start-ups and small emerging growth companies. She has been with Rankin McKenzie as a Partner since 2019.  Ms. Huff's principal responsibilities at Pharmatrophix are day-to-day accounting, financial reporting for management, investors and the Board of Directors, as well as budgeting and forecasting. She is a native of Ohio and holds a Bachelor’s degree from West Virginia University.

Kathy Huff

PharmatrophiX engages teams of advisors consisting of senior industry and academic experts in all
stages of drug development and in global strategies and approaches in Alzheimer's and
other neurological diseases.